Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 370-374

  Iacopino, Fortunata ^a   Pinto, Francesco ^a   Bertaccini, Alessandro ^b   Calarco, Alessandro ^a   Proietti, Gabriella ^a   Totaro, Angelo ^a   Martorana, Giuseppe ^b   Bassi, Pierfrancesco ^a   Sica, Gigliola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

IL 6; Prostate cancer; Serum markers; Soluble E cadherin

Indexed keywords

INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYMATIC ASSAY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; STUDENT T TEST;

AGED; CADHERINS; COHORT STUDIES; HUMANS; INTERLEUKIN-6; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861557288     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1785     Document Type: Article

References (30)

1. Strope SA and Andriole GL: Prostate cancer screening: current status and future perspectives. Nat Rev Urol 7: 487-493, 2010.
2. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, Greenfield S and Litwin MS: Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117: 2058-2066, 2011.
3. Steuber T, O'Brien MF and Lilja H: Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 54: 31-40, 2008.
4. Beachy SH and Repasky EA: Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 57: 759-775, 2008.
5. De Wever O, Derycke L, Hendrix A, De Meerleer G, Godeau F, Depypere H and Bracke M: Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 24: 685-697, 2007. (Pubitemid 350159736)
6. Pontes-Junior J, Reis ST, Dall'Oglio M, Neves de Oliveira LC, Cury J, Carvalho PA, Ribeiro-Filho LA, Moreira Leite KR and Srougi M: Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J Carcinog 8: 3, 2009.
7. Waugh DJ, Wilson C, Seaton A and Maxwell PJ: Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4595-4604, 2008. (Pubitemid 351589184)
8. Cavallaro U and Dejana E: Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 12: 189-197, 2011.
9. Jeanes A, Gottardi CJ and Yap AS: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27: 6920-6929, 2008.
10. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A and Balaji KC: Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 23: 402-406, 2005. (Pubitemid 41654506)
11. Musial J, Sporny S and Nowicki A: Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol 58: 235-243, 2007. (Pubitemid 351428300)
12. van Kilsdonk JW, van Kempen LC, van Muijen GN, Ruiter DJ and Swart GW: Soluble adhesion molecules in human cancers: sources and fates. Eur J Cell Biol 89: 415-427, 2010.
13. Weiss JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W and Schwarte-Waldhoff I: Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 128: 1384-1392, 2011.
14. Chung Y, Law S, Kwong DL and Luk JM: Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 24: 49-55, 2011.
15. Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, Constantopoulos SH and Dalavanga Y: Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 138: 1173-1179, 2010.
16. Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, Eggel M, Gschwend JE, Rubin MA and Day ML: Assessment of a fragment of E-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 92: 2018-2023, 2005. (Pubitemid 40897424)
17. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA and Day ML: The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 9: 6447-6452, 2003. (Pubitemid 38031832)
18. Ahmed MI, Abd-Elmotelib F, Farag RM, Ziada NA and Khalifa A: Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males. Clin Biochem 32: 439-445, 1999. (Pubitemid 29536176)
19. Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG and Stack MS: Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67: 2030-2039, 2007. (Pubitemid 46424220)
20. Neurath MF and Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89, 2011.
21. Alcover J, Filella X, Luqué P, Molina R, Izquierdo L, Augé JM and Alcaraz A: Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res 30: 4369-4372, 2010.
22. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999, 2004. (Pubitemid 38375558)
23. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C and Leto G: Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 26: 10-15, 2009.
24. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM and Shariat SF: Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69: 886-894, 2009.
25. Pedrazzani C, Caruso S, Corso G, Marrelli D, Neri A, Berardi A and Roviello F: Influence of age on soluble E-cadherin serum levels prevents its utility as a disease marker in gastric cancer patients. Scand J Gastroenterol 43: 765-766, 2008. (Pubitemid 351868717)
26. Carroll JE, Low CA, Prather AA, Cohen S, Fury JM, Ross DC and Marsland AL: Negative affective responses to a speech task predict changes in interleukin (IL)-6. Brain Behav Immun 25: 232-238, 2011.
27. Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodell MM, Weatherbee JA, Young MR, Nemchausky BM and Scheving LE: Circadian characteristics of circulating interleukin- 6 in men. J Allergy Clin Immunol 95: 1029-1035, 1995.
28. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M and Kato I: Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 69: 580-585, 1994. (Pubitemid 24076484)
29. Jurczok A, Zacharias M, Wagner S, Hamza A and Fornara P: Prospective non-randomized evaluation of four mediators of the systemic response after extraperitoneal laparoscopic and open retropubic radical prostatectomy. BJU Int 99: 1461-1466, 2007. (Pubitemid 47164817)
30. Lin MT, Yeh SL, Wu MS, Lin JT, Lee PH, Liaw KY, Chang KJ and Chen WJ: Impact of surgery on local and systemic responses of cytokines and adhesion molecules. Hepatogastroenterology 56: 1341-1345, 2009.